Brief: Caliway: New Drug CBL-514 Phase II Clinical Results' Demonstrated Efficacy
21/09/2026 11:11
BRIEF-Caliway: New Drug CBL-514 Phase II Clinical Results' Demonstrated Efficacy Sept 21 (Reuters) - CALIWAY BIOPHARMACEUTICALS CO., LTD. 6919.TW:
SAYS NEW DRUG CBL-514 PHASE II CLINICAL RESULTS' PRIMARY EFFICACY ENDPOINT DEMONSTRATED STATISTICALLY SIGNIFICANT EFFICACY
Source text: ID:nMOP97Qd9y
Further company coverage: 6919.TW
(Reporting by Hong Kong newsroom)
((donny.kwok@thomsonreuters.com; +852 3462 7745;))
Recent news on CALIWAY BIOPHARMACEUTICALS
See all newsBrief: Caliway: New Drug CBL-514 Phase II Clinical Results' Demonstrated Efficacy
Brief: Caliway Says A Phase 2B Study For Reducing Abdominal Subcutaneous Fat Met All Main Goals
Brief: Caliway Announced EMA Orphan Drug Designation Granted To CBL-514 For Dercum's Disease Treatment
Brief: Caliway Biopharmaceuticals Expects IND Approvals For Cbl-514